mobile-logo

January 2012

31 Jan

Physiomics to enter new therapeutic area with appointment of SAB member

by Charmaine Fraser
in Investor News / RNS
Comments

Physiomics plc (AIM: PYC), the Oxford, UK-based systems biology company, is pleased to announce its intention to increase the scope of its offering through the development of a new modelling service to predict the cardiac toxicity of drugs.  The Directors believe that this new service will be of particular interest to biotechnology companies looking to streamline their drug discovery programmes and improve the success rates...

Read More
26 Jan

Update on 3D Culture Collaboration with InSphero

by Charmaine Fraser
in Investor News / RNS
Comments

  The below excerpt has been taken from InSphero’s latest newsletter, 'Upgrade Your Cell-Based Assays to 3D', discussing the collaboration between InSphero and Physiomics plc. Customer case study: 3D microtissue growth and drug response – virtual and in vitro models InSphero’s customer Physiomics plc develops computational systems-biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. The Oxford (UK)-based company has created detailed...

Read More
17 Jan

Biosimulation Scientist

by Charmaine Fraser
in Other News
Comments

Physiomics is an Oxford-based systems biology company specialised in computational modelling of complex biological systems. Our models are based on sets of mathematical equations that simulate key biological processes, and are used by pharmaceutical companies to accelerate their internal drug discovery and development programs. We have an opportunity for a Biosimulation Scientist to join our technical team to work on projects related to drug development....

Read More